CSE: WBIO

Last: 1.24

Change: -0.14

Vol: 357,104

About Us
Portfolio
- Overview
- Brain Cancer
  - WPD101
  - Berubicin
  - WP1066
- Pancreatic Cancer
  - WP1066
  - WP1732
- Melanoma
  - WPD102
- Other Cancers
  - WPD103
  - WP1220
  - Annamycin
Investors
News & Media
- Latest News
- Events
Procurement/RFP
Contact Us

About Us
Portfolio
- Overview
- Brain Cancer
  - WPD101
  - Berubicin
  - WP1066
- Pancreatic Cancer
  - WP1066
  - WP1732
- Melanoma
  - WPD102
- Other Cancers
  - WPD103
  - WP1220
  - Annamycin
Investors
News & Media
- Latest News
- Events
Procurement/RFP
Contact Us

CSE: WBIO

Last: 1.24

Change: -0.14

Vol: 357,104

Presentation

Investors

Presentation
Stock Information
Share Structure
Financial Reports

Corporate Presentation
Download Fact Sheet
Download

Subscribe to our Newsletter

About Us
Portfolio
Investors
News & Media
- Latest News
- Events
Procurement/RFP
Contact Us

Corporate Head Office

WPD Pharmaceuticals sp. z o.o.
Żwirki i Wigury 101, 02-089 Warszawa, Polska
NIP: 5252721500, KRS: 0000693186
tel: +48 515 262 381

Canada Corporate Office

Vancouver Office
Suite 1080, 789 West Pender Street
Vancouver, BC
V6C 1H2

Careers Privacy Policy Cookies Policy © 2020 WPD Pharmaceuticals. All Rights Reserved

Designed and Powered by BLENDER